248 related articles for article (PubMed ID: 36421360)
1. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.
Mohamed A; Azmi AS; Asa SL; Tirumani SH; Mahipal A; Cjakrabarti S; Bajor D; Selfridge JE; Kaseb AO
Curr Oncol; 2022 Nov; 29(11):9018-9030. PubMed ID: 36421360
[TBL] [Abstract][Full Text] [Related]
2. Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC).
Mohamed A; Vijayvergia N; Kurian M; Liu L; Fu P; Das S
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681675
[No Abstract] [Full Text] [Related]
3. Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas.
Gile JJ; McGarrah PW; Leventakos K; Sonbol MB; Starr JS; Eiring RA; Hobday TJ; Halfdanarson TR
J Neuroendocrinol; 2023 May; 35(5):e13283. PubMed ID: 37229903
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms.
Al-Toubah T; Halfdanarson T; Gile J; Morse B; Sommerer K; Strosberg J
ESMO Open; 2022 Feb; 7(1):100364. PubMed ID: 34973511
[TBL] [Abstract][Full Text] [Related]
6. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.
Ooki A; Osumi H; Fukuda K; Yamaguchi K
Cancer Metastasis Rev; 2023 Sep; 42(3):1021-1054. PubMed ID: 37422534
[TBL] [Abstract][Full Text] [Related]
7. Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden.
Kang NW; Tan KT; Li CF; Kuo YH
Curr Oncol; 2021 Nov; 28(6):4587-4596. PubMed ID: 34898561
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
Xu JX; Wu DH; Ying LW; Hu HG
World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
Weber MM; Fottner C
Oncol Res Treat; 2018; 41(5):306-312. PubMed ID: 29742518
[TBL] [Abstract][Full Text] [Related]
11. Durable response to combination radiotherapy and immunotherapy in EP-resistant lung large-cell neuroendocrine carcinoma with
Qin Y; Yu M; Zhou L; Jiang L; Huang M
Immunotherapy; 2020 Mar; 12(4):223-227. PubMed ID: 32156177
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
Klein O; Kee D; Markman B; Michael M; Underhill C; Carlino MS; Jackett L; Lum C; Scott C; Nagrial A; Behren A; So JY; Palmer J; Cebon J
Clin Cancer Res; 2020 Sep; 26(17):4454-4459. PubMed ID: 32532787
[TBL] [Abstract][Full Text] [Related]
14. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice.
Bruera G; Giuliani A; Romano L; Chiominto A; Di Sibio A; Mastropietro S; Cosenza P; Ricevuto E; Schietroma M; Carlei F;
BMC Cancer; 2019 Oct; 19(1):960. PubMed ID: 31619203
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
17. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
De Divitiis C; von Arx C; Grimaldi AM; Cicala D; Tatangelo F; Arcella A; Romano GM; Simeone E; Iaffaioli RV; Ascierto PA; Tafuto S;
J Transl Med; 2016 May; 14(1):113. PubMed ID: 27142424
[TBL] [Abstract][Full Text] [Related]
18. EpiCO (epirubicin, cyclophosphamide and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms.
Munker S; Vogelhuber M; Bornschein J; Stroszczynski C; Evert M; Schlitt H; Herr W; Teufel A
Z Gastroenterol; 2020 Feb; 58(2):133-136. PubMed ID: 31896137
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study.
Özdirik B; Jann H; Bischoff P; Fehrenbach U; Tacke F; Roderburg C; Wiedenmann B
Medicine (Baltimore); 2021 Jan; 100(1):e23835. PubMed ID: 33429744
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
Fazio N; Abdel-Rahman O
Curr Treat Options Oncol; 2021 Feb; 22(3):19. PubMed ID: 33559013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
